JO
DSGN icon

John Overdeck’s Design Therapeutics DSGN Stock Holding History

John Overdeck’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$476K Buy
32,925
+16,625
+102% +$207K ﹤0.01% 4194
2026
Q1 		$173K Sell
16,300
-29,937
-65% -$303K ﹤0.01% 4305
2025
Q4 		$434K Sell
46,237
-13,000
-22% -$102K ﹤0.01% 3390
2025
Q3 		$446K Sell
59,237
-30,074
-34% -$151K ﹤0.01% 3032
2025
Q2 		$301K Sell
89,311
-39,436
-31% -$148K ﹤0.01% 2787
2025
Q1 		$497K Sell
128,747
-75,184
-37% -$359K ﹤0.01% 2525
2024
Q4 		$1.26M Sell
203,931
-100,313
-33% -$581K ﹤0.01% 2026
2024
Q3 		$1.64M Sell
304,244
-98,471
-24% -$463K ﹤0.01% 1798
2024
Q2 		$1.35M Sell
402,715
-19,320
-5% -$75.3K ﹤0.01% 1805
2024
Q1 		$1.7M Sell
422,035
-6,136
-1% -$16.4K ﹤0.01% 1600
2023
Q4 		$1.13M Buy
428,171
+364,336
+571% +$835K ﹤0.01% 2003
2023
Q3 		$151K Sell
63,835
-51,947
-45% -$242K ﹤0.01% 2694
2023
Q2 		$729K Sell
115,782
-63,314
-35% -$387K ﹤0.01% 2135
2023
Q1 		$1.03M Buy
179,096
+144,003
+410% +$1.08M ﹤0.01% 1850
2022
Q4 		$360K Buy
+35,093
New +$476K ﹤0.01% 2169

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

John Overdeck's DSGN Position: Q2 2026 in Review

John Overdeck increased its Design Therapeutics (DSGN) stake by 102% in Q2 2026, buying an estimated $207K and bringing the position to 32,925 shares worth $476K. The position accounts for ﹤0.01% of the portfolio, ranked #4194.

John Overdeck first reported a position in DSGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.7M in Q1 2024. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • John Overdeck held 32,925 shares of Design Therapeutics worth $476K as of Q2 2026.
  • John Overdeck bought 16,625 Design Therapeutics shares in Q2 2026, an estimated $207K.
  • Design Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4194 holding.
  • John Overdeck first reported a position in Design Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • John Overdeck's Design Therapeutics position peaked at $1.7M in Q1 2024.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.